Preferred Label : Anti-ILT2/Anti-ILT4 Bispecific Antibody PF-07826390;
NCIt synonyms : Anti-LILRB1/LILRB2 Bispecific Antibody PF-07826390; ILT2 x ILT4 Bispecific Antibody PF-07826390; Anti-LILRB1/2 Bispecific Antibody PF-07826390; Anti-ILT2/ILT4 Bispecific Antibody PF-07826390;
NCIt definition : A humanized immunoglobulin G1 (IgG1) bispecific antibody directed against the inhibitory
immune checkpoint receptors immunoglobulin (Ig)-like transcript 2 (ILT2; leukocyte
immunoglobulin-like receptor subfamily B member 1; LILRB1; leukocyte immunoglobulin-like
receptor 1; LIR1; monocyte/macrophage immunoglobulin-like receptor 7; MIR-7; CD85j)
and ILT4 (LILRB2; LIR2; MIR-10; CD85d), with potential immunomodulating and antineoplastic
activities. Upon administration, anti-ILT2/anti-ILT4 bispecific antibody PF-07826390
targets and binds to both ILT2 and ILT4. This prevents the binding of ILT2 and ILT4
ligands, including the major histocompatibility complex class I (MHC I) molecules
human leukocyte antigen (HLA)-A, HLA-B, HLA-C and HLA-G, to the ILT2 and ILT4 receptors
and prevents ILT2- and ILT4-mediated signaling. This inhibits ILT2- and ILT4-mediated
immune suppression and may activate both innate and adaptive immune responses, including
natural killer (NK) and CD8 T-cell tumor cell killing, and macrophage phagocytosis
of tumor cells. ILT2 and ILT4, expressed on myeloid cells in the tumor microenvironment
(TME), are upregulated in various cancer types and play an important role in tumor
immune evasion. ILT2 is also expressed on various innate and adaptive immune cells
including NK cells, B-cells and a subset of cytolytic T-cells.;
Molecule name : PF-07826390; PF 07826390;
Origin ID : C209282;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
